{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:45Z","timestamp":1793042685314,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113458","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:57:27Z","timestamp":1700535447000},"page":"113458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8123-4065","authenticated-orcid":false,"given":"Filip","family":"Janku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-6099","authenticated-orcid":false,"given":"Gopakumar","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Maur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0470-9482","authenticated-orcid":false,"given":"Sumit","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Baffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Buigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesselina","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113458_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205059","article-title":"Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers","volume":"13","author":"Dillon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113458_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOG.0000000000000382","article-title":"Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants","volume":"33","author":"Giri","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ejca.2023.113458_bib3","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2023.113458_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111717","article-title":"The current understanding on the impact of KRAS on colorectal cancer","volume":"140","author":"Meng","year":"2021","journal-title":"Biomed Pharm"},{"key":"10.1016\/j.ejca.2023.113458_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2022.09.022","article-title":"Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy","volume":"167","author":"ElNaggar","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113458_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04948-3","article-title":"BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases","volume":"7","author":"Fakhruddin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.113458_bib8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2023.113458_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1634\/theoncologist.2009-0233","article-title":"Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery","volume":"15","author":"Tejpar","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2023.113458_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00221","article-title":"BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition","author":"Moujaber","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK Pathway in KRAS-Driven Tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2023.113458_bib12","first-page":"665","article-title":"Drug resistance in targeted cancer therapies with RAF inhibitors","volume":"4","author":"Degirmenci","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejca.2023.113458_bib13","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors","volume":"27","author":"Monaco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113458_bib14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2023.113458_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1078966","article-title":"Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma","volume":"5","author":"Bradley","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2023.113458_bib16","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: A review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113458_bib18","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.3390\/cancers12103057","article-title":"From conventional therapies to immunotherapy: melanoma treatment in review","volume":"12","author":"Kuryk","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113458_bib19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAFV600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.113458_bib21","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.113458_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072531","article-title":"Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade","volume":"21","author":"Shin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2023.113458_bib23","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113458_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-19-0681","article-title":"A Phase I study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer","volume":"19","author":"Sullivan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2023.113458_bib26","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2019.37.15_suppl.3000","article-title":"Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS , or NRAS mutations: Phase I study","volume":"37","author":"Kim","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib27","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, open-label, dose-escalation\/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113458_bib28","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/sj.emboj.7600309","article-title":"The Ras\/Raf\/ERK signalling pathway drives Schwann cell dedifferentiation","volume":"23","author":"Harrisingh","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2023.113458_bib29","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.ejca.2023.113458_bib30","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.18632\/oncotarget.26753","article-title":"Biomarker results from a phase II study of MEK1\/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma","volume":"10","author":"van Herpen","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2023.113458_bib31","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: Results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2023.113458_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/mdx367.043","article-title":"Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): final analysis","volume":"28","author":"Olszanski","year":"2017","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:22Z","timestamp":1760733802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"alternative-id":["S0959804923007608"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113458","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113458"}}